Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
AQP4
Recent Posts
- Ultomiris shows sustained disease control in NMOSD analysis
- What NMOSD has taught me about showing up for the people I love
- Real-world data backs clinical safety profile of Enspryng for NMOSD
- Bladder dysfunction: The NMOSD plot twist that nobody wants
- Older age at NMOSD onset may raise disease relapse risk